Executive Summary
Wegovy · Obesity · Turkey
Consumer AI answers · Aug 2026 cycle · 12 approved prompts · 3 AI engines
12-month trajectory
Mention and recommendation rate, all engines combined.
Strongest competitor
Highest recommendation rate in this audience.
Dominant attribute
Highest attribute score in AI answers.
Convenience
Score 98
Weakest attribute
Largest improvement area.
Access / availability
Score 49
Positioning statement
All engines · Consumer AI · Turkey
Wegovy occupies a 'proven, convenient injection' territory. Its strongest differentiation is evidence strength and safety profile; the main vulnerability is access and reimbursement narrative, especially in local Turkish market discussions.
Top cited sources
Share of source appearances in this audience, all engines.
Wikipedia / general web
General web · Global
Hospital websites (TR)
Local provider · Local
STEP trials / PubMed
Publication · Global
Social media / forums
Social · Local
Turkish Endocrinology Society
Medical society · Local
Local Turkish sources make up 43% of appearances, global sources 57%.
Priority area
Top item from the Action page.
Weakest Attribute: Access and availability is the weakest attribute in both audiences.
- Turkish obesity guidelines — Little clarity on where pharmacotherapy sits locally.
- Hospital websites (TR) — Access information is fragmented and often out of date.
- Social media / forums — Fills the reimbursement gap with unverified claims.